dr. rule on the combination of venetoclax and ibrutinib in mcl
Published 4 years ago • 339 plays • Length 1:27Download video MP4
Download video MP3
Similar videos
-
1:22
dr. kaplan on the combination of ibrutinib and venetoclax in mcl
-
1:56
dr. tam on the combination of ibrutinib plus venetoclax in mantle cell lymphoma
-
1:08
dr. tam on the toxicities of ibrutinib plus venetoclax in mcl
-
0:15
copy of dr. kaplan on the combination of ibrutinib and venetoclax in mcl
-
1:08
dr. tam on the toxicity of ibrutinib plus venetoclax in mcl
-
1:09
dr. ritchie on the immunologic impact of long-term venetoclax/ibrutinib in r/r mcl
-
1:28
dr. ritchie on immunological recovery with venetoclax and ibrutinib in mcl
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:33
dr. jacobs on the efficacy of ibrutinib and acalabrutinib in patients with mcl
-
1:27
dr. ritchie on immunological response to venetoclax/ibrutinib in r/r mcl
-
2:12
dr. brander on the safety and efficacy of ibrutinib/venetoclax in cll
-
1:56
dr. rule on the role of btk inhibitors in mcl
-
1:21
ibrutinib, rituximab and venetoclax in the treatment of patients with newly diagnosed mcl
-
1:09
dr. goy discusses ibrutinib with venetoclax in mcl
-
0:47
dr. davids on the potential utility of frontline ibrutinib/umbralisib in mcl and cll
-
1:31
dr. smith on the rationale behind the fixed duration trial for ibrutinib/venetoclax in cll
-
1:52
dr. eyre on btk inhibitors in combination with venetoclax for mcl
-
1:36
dr. rule on long-term follow-up of ibrutinib monotherapy in relapsed/refractory mcl
-
1:47
dr. leslie on the role of btk inhibitors in relapsed/refractory mcl